Investment Thesis
Krystal Biotech demonstrates exceptional fundamental strength with 48.1% net margins, 33.9% revenue growth, and explosive 129.7% net income growth driven by strong operating leverage. The company maintains a fortress balance sheet with $501.3M cash, minimal debt, and excellent free cash flow generation ($73.2M, 62.9% FCF margin), positioning it to weather biotech headwinds and fund long-term growth.
Strengths
- Exceptional profitability: 48.1% net margin and 46.1% operating margin indicate strong pricing power and cost control
- Outstanding cash generation: $73.2M free cash flow with 62.9% margin demonstrates revenue quality and sustainability
- Fortress balance sheet: $501.3M cash, only $4.3M debt, minimal financial risk with 9.46x current ratio
- Accelerating bottom-line growth: Net income growth (129.7% YoY) outpacing revenue growth (33.9%) shows operating leverage
- Low capex intensity: Only $7.1M capex needed relative to cash generation suggests efficient, asset-light model
Risks
- Capital efficiency concerns: ROE of 4.4% and ROA of 4.0% despite strong profitability suggests underdeployed capital and excess cash accumulation
- Biotech-specific risks: Regulatory approval uncertainties, product pipeline execution, and potential competitive threats inherent to sector
- Margin sustainability risk: 48.1% net margin may not be sustainable if product mix shifts or competitive pressures increase
- Incomplete profitability visibility: Gross margin data unavailable prevents full assessment of product-level profitability
- Growth deceleration potential: Whether 33.9% revenue growth can be sustained remains uncertain; net income growth appears non-linear
Key Metrics to Watch
- Gross margin trends and product-level profitability
- Quarterly revenue growth sustainability and any signs of deceleration
- Operating cash flow consistency and working capital management
- Strategic deployment or capital allocation of accumulated $501.3M cash reserve
- Regulatory approval progress and product pipeline advancement
Financial Metrics
Revenue
116.4M
Net Income
55.9M
EPS (Diluted)
$1.83
Free Cash Flow
73.2M
Total Assets
1.4B
Cash
501.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
46.1%
Net Margin
48.1%
ROE
4.4%
ROA
4.0%
FCF Margin
62.9%
Balance Sheet & Liquidity
Current Ratio
9.46x
Quick Ratio
9.06x
Debt/Equity
0.00x
Debt/Assets
8.6%
Interest Coverage
N/A
Long-term Debt
4.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:35:55.399099 |
Data as of: 2026-03-31 |
Powered by Claude AI